A “LIVE” globally-broadcasted, Internet-only “virtual” video satellite symposium at 1PM (Eastern Time USA) on May 30, 2020 during the annual ASCO meeting.
TITLE: The Expanding Number of Driver Mutations for NSCLC: How are They Revealed by Current & Emerging Molecular Tests? What are Their Standards of Care and Other Treatment Options? How are Patients Without Mutations Tested and Treated?
The number of driver mutations in NSCLC has been expanding beyond the traditional molecular alterations such as EGFR, ALK & ROS1. Today, driver mutations include NTRK, MET exon 14, KRAS, RET, HER2, BRAF & less common EGFR mutations. FDA-approved TKIs for driver mutations in NSCLC include five for EGFR, five for ALK, two for ROS1, two for NTRK, one for MET exon 14, and one for RET fusions. In addition, there is a major role for immune therapy, and for molecular diagnostic testing to help guide the selection of checkpoint inhibition in the first-line setting for NSCLC patients without mutations.
For all treatment-naïve NSCLC patients, proper molecular testing must be done before initial therapy begins in order to identify the specific driver mutation and corresponding optimal TKI therapy, or in the absence of such driver mutations, to facilitate the first-line use of optimal immune checkpoint inhibitor therapy.
Faculty members will ask questions of the participants. Questions will be treatment-related and derived from the clinical case studies. The participants can submit questions to the faculty and up vote their questions at any time. And although virtual, it provides the same ability for extensive interaction between the participants and faculty as can be achieved with any in-person symposium.